Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.

@article{Kottke2010AntiangiogenicCT,
  title={Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.},
  author={Timothy J Kottke and Geoff Hall and Jos{\'e} Zago Pulido and Rosa Mar{\'i}a D{\'i}az and Jill Thompson and H. G. Chong and Peter Selby and Matthew C. Coffey and Hardev Pandha and John D. Chester and Alan F Melcher and Kevin Harrington and Richard G. Vile},
  journal={The Journal of clinical investigation},
  year={2010},
  volume={120 5},
  pages={1551-60}
}
Clinical trials of oncolytic virotherapy have shown low toxicity and encouraging signs of efficacy. However, it remains critically important to develop methods for systemic viral delivery if such therapies are to be clinically implemented to treat established tumors. In this respect, much effort is being focused on combining oncolytic viruses with standard treatment modalities such as inhibitors of VEGF165 (an alternatively spliced isoform of VEGF-A) signaling, which are widely used to treat… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

Similar Papers

Loading similar papers…